Abstract 1554P
Background
We conducted a clinical trial evaluating safety and efficacy of T-mab plus N-mab with S-1/Capecitabine plus oxaliplatin (UMIN000034222). The aim of this study was to investigate the clinical significance of ERBB2 amplification (amp.) and TMB-H for this new combination therapy.
Methods
Patients were treated with S-1 80 mg/m2/day or Capecitabine 2000 mg/m2/day on days 1-14 with oxaliplatin 130 mg/m2, N-mab 360mg, and T-mab 8mg/kg for initial treatment, and subsequently with 6 mg/kg on day, repeated every 3 weeks. Pretreatment primary tumor samples were collected for whole exome sequencing (WES) and immunohistochemistry (IHC).
Results
Among 42 patients enrolled in this clinical trial, WES was performed on 23 patients. ERBB2 amp. (≥ 6 copies) was observed in 15 patients (65%). Fourteen (93.3%) of these 15 patients with ERBB2 amp. and 2 (25%) of 8 patients without ERBB2 amp. were IHC3+, respectively (p = 0.002). There was a weak positive correlation between ERBB2 copy number and PFS (r = 0.449, p = 0.032). Patients with ERBB2 amp. showed longer PFS than those without ERBB2 amp. (mPFS: 16.3 vs 5.8 months, HR = 0.70 [95%CI 0.24-2.09], p = 0.522). In particular, 7 patients with high ERBB2 copy number (≥ 50) showed remarkably longer PFS and a higher response rate than 16 patients with < 50 (mPFS: 20.8 vs 6.7 months, HR = 0.40 [95%CI 0.12-1.30], p = 0.117, response rate: 100% vs 63%, p = 0.124). TMB-H (≥ 10 muts/Mb) was observed in 6 patients (26%), and these patients also showed substantially longer PFS than those with TMB-L (mPFS: 16.3 vs 9.2 months, HR = 0.43 [95%CI 0.12-1.51], p = 0.172) with a comparable response rate (83% vs 73%). Eleven patients with ERBB2 copy number ≥ 50 or TMB-H showed significantly longer PFS (mPFS: 20.8 vs 5.8 months, HR = 0.28 [95%CI 0.09-0.88], p = 0.021) and OS (mOS: not reached vs 15.0 months, HR = 0.10 [95%CI 0.01-0.78], p = 0.007) and a higher response rate (91% vs 58%, p = 0.155) than the remaining 12 patients.
Conclusions
High ERBB2 copy number and TMB-H may be a candidate biomarker for this new combination therapy including T-mab and N-mab in patients with HER2-positive advanced gastric cancer.
Clinical trial identification
UMIN000034222.
Editorial acknowledgement
Legal entity responsible for the study
Daisuke Takahari.
Funding
Ono Pharmaceutical Co., Ltd.
Disclosure
H. Shoji: Financial Interests, Personal, Advisory Board: Ono Pharmaceutical Co., Ltd., Zymeworks inc.; Financial Interests, Institutional, Local PI: Ono Pharmaceutical Co., Ltd., MSD, Astellas, Amgen, Daiichi Sankyo; Financial Interests, Institutional, Funding: Ono Pharmaceutical Co., Ltd., Takeda Pharmaceuticals. K. Minashi: Financial Interests, Institutional, Research Grant: Amgen, Taiho Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Astellas Pharmaceutical Co., Ltd. H. Hara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, MSD, Ono, Bayer, Chugai, Lilly, Merck Biopharma, Taiho, Takeda, Yakult, Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Janssen, Merck Biopharma, MSD, Ono, Taiho, ALX oncology. N. Boku: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Eli Lilly, Ono Pharmaceutical, Taiho, Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Takeda Pharmaceutical, Ono Pharmaceutical. K. Yamaguchi: Financial Interests, Personal, Invited Speaker: Taiho; Financial Interests, Personal, Expert Testimony: Daiichi Sankyo, Bristol Myers Squibb, Ono, Eli Lilly Japan; Financial Interests, Institutional, Funding: Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21